Application of posaconzole in prophylactic antifungal treatment of patients with hematological malignancies
10.3760/cma.j.issn.1009-9921.2018.06.002
- VernacularTitle:泊沙康唑预防性抗真菌治疗在血液系统恶性肿瘤患者中的应用
- Author:
Chenjing YE
1
;
Wenbin XU
;
Qing YU
;
Chao WU
;
Lei HUANG
;
Jiong HU
;
Junmin LI
;
Hua YAN
Author Information
1. 200025,上海交通大学医学院附属瑞金医院特需医疗中心
- Keywords:
Hematological neoplasms;
Mycoses;
Posaconzole
- From:
Journal of Leukemia & Lymphoma
2018;27(6):326-329
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effec t and safety of posaconzole in prophylactic antifungal treatment of high-risk patients with hematological malignancies. Methods The effect of posaconzole on prevention of invasive fungal disease (IFD) during chemotherapy in 102 patients with hematological malignancies in Shanghai Ruijin Hospital from February 2014 to April 2017 were analyzed retrospectively. The correlation analysis was carried out by Spearman analysis. Results A total of 102 patients were included, and only 2 (1.96%) patients had IFD. 2 patients died because of development of hematological malignancies. 11 (10.8%) patients had to discontinuation of posaconzole because of sever adverse events. Two patients with IFD and 1 case of undiagnosed IFD had to discontinue posaconzole. The total rate of discontinuation was 13.7 % (14/102). There was no correlation between the time of using pothiazol and the time of hospitalization (rs= -0.02, P= 0.853) and the time of neutrophilic deficiency (rs= 0.167, P= 0.113), but the time of hospitalization was positively correlated with the time of neutrophilic deficiency (rs = 0.448, P=0.000). Conclusion Posaconzole could effectively and safely prevent IFD in patients with hematological malignancies.
